Your SlideShare is downloading. ×
Organovo: 3 Things to Know
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Organovo: 3 Things to Know

3,932
views

Published on

Published in: Economy & Finance, Business

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
3,932
On Slideshare
0
From Embeds
0
Number of Embeds
17
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • Third paragraph http://ir.organovo.com/news/press-releases/press-releases-details/2014/Organovo-Comments-on-Misleading-and-Inaccurate-Reports/default.aspx
    Second question http://www.organovo.com/investors/frequently-asked-questions
  • Transcript

    • 1. 3 Things You Need to Know
    • 2. On one hand…  In April, the company said many short attacks were, “exceptionally— and likely intentionally— misleading.”  The company filed a libel lawsuit against one research firm putting out short attacks.  While the facts being used might be in question, there’s no doubt this is a speculative company.  Essentially no product revenue has ever been created.  Management has had a number of dilutive offerings. On the other…
    • 3.  Organovo was expected to finish functional validation of its 3-D liver assays in March, and have them to Key Opinion Leaders (KOLs) by April.  The company reached both of those goals by late January.  Demand has been strong enough for these assays that the company is conducting liver toxicity tests for selected customers ahead of the product’s December 2014 launch.
    • 4.  Organovo has not provided a timeline for when KOL findings will be released.  However, since the liver assays will launch prior to 2015, KOL opinions will likely be released before that time.  Investors likely won’t get a chance to see revenue numbers before mid-2015 earnings are released, so these KOL opinions will have a major impact on the company’s stock…and the investment thesis for shareholders.
    • 5. Investing in cutting-edge companies like Organovo is fun, but such speculative companies alone shouldn’t dominate your portfolio. To get a list of solid, steady, dividend payers, check out our special free report: Top Dividend Stocks for the Next Decade

    ×